Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity
Markus Hoffmann, Heike Hofmann-Winkler, Joan C. Smith, Nadine Krüger, Prerna Arora, Lambert K. Sørensen, Ole Schmeltz Søgaard, Jørgen Bo Hasselstrøm, Michael Winkler, Tim Hempel, Lluı́s Raich, Simon Olsson, Olga Danov, Danny David Jonigk, Takashi Yamazoe, , Stefan Pöhlmann
This study shows camostat mesylate inhibits SARS-CoV-2 by blocking TMPRSS2 and its metabolite GBPA also has antiviral activity, suggesting no resistance through TMPRSS2-related proteases.
EBioMedicine · Mar 1, 2021Peer-reviewedMolecular Biology